Skip to content
Menu

Spruce Biosciences, Inc. SPRB

Full chart Compare
Set alert

Price alert · SPRB

All alert types
38.00 USD -2.49 (-6.15%)

Regular-session close

38.00 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

38.00 Day range 40.96
38.00 52-week range 112.26
YTD
-56.38%
1 year
-62.97%

5D -6.17 (-13.70%)

404244MonTueWedThuFri38.86
Market cap
109.21M
Revenue (ttm)
7.10M
EPS (ttm)
-33.29
Shares out
41.30M
Forward P/E
-0.41
YTD return
-56.38%
1-year return
-62.97%
50-day average
0.50446
Volume
108.29K
Avg volume
88.62K
Open
39.97
Previous close
40.49
Day's range
38.00 – 40.96
52-week range
38.00 – 112.26
Analysts
Hold
Price target
1.83 (-95.2%)

Key statistics

200-day average
0.668845
Enterprise value
-40.58M
Price / sales
2.20
Price / book
0.30
Revenue growth
-80.40%
Free cash flow
-35.07M
Total cash
60.05M
Total debt
2.96M
Return on equity
-57.55%
Short % of float
0.08%

Fundamental scorecard

4 of 25 checks passed on SPRB’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SPRB Revenue — quarterly 0
SPRB Net income — quarterly -24.01M
SPRB EPS — quarterly -8.51

Earnings

SPRB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 11, 2024Sep 1, 2024-0.27-0.21+0.06+22.22%
Aug 12, 2024Jun 1, 2024-0.33-0.22+0.11+33.33%
Aug 12, 2024Jun 1, 2024-0.33———
May 13, 2024Mar 1, 2024-0.32-0.28+0.04+12.50%
May 13, 2024Mar 1, 2024-0.32———
Mar 13, 2024Dec 1, 2023-0.41———

Upgrades / downgrades

SPRB analyst upgrades and downgrades
DateFirmActionFromTo
Dec 16, 2024HC Wainwright & Co.reitNeutralNeutral
Dec 12, 2024GuggenheimreitNeutralNeutral
Dec 11, 2024JMP SecuritiesdownMarket OutperformMarket Perform
Dec 11, 2024RBC CapitalreitSector PerformSector Perform
Dec 11, 2024OppenheimerdownOutperformPerform
Nov 12, 2024RBC CapitalreitSector PerformSector Perform

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on SPRB — it syncs with the Stock Master app.

Insider holders

SPRB insider holders
InsiderRelationLatest transactionDateShares held
CHARLTON RALPH WILLIAM IIIOfficerConversion of Exercise of derivative securityDec 15, 2024161,339
GHARIB SAMIR MPresidentConversion of Exercise of derivative securityDec 15, 2024350,550
NOVO HOLDINGS A/SBeneficial Owner of more than 10% of a Class of SecuritySaleMar 20, 20242,550,000
O DONNELL NIALLDirectorPurchaseFeb 15, 20230
ODONNELL NIALLDirectorPurchaseFeb 15, 20230
SZWARCBERG JAVIER B M.D.Chief Executive OfficerConversion of Exercise of derivative securityDec 15, 2024467,191

Institution ownership

SPRB institution ownership
Holder% heldSharesValueReported
Rivervest Venture Management LLC7.11%2,936,2811.11MSep 29, 2024
Carlyle Group Inc.7.01%2,896,5181.09MSep 29, 2024
Rock Springs Capital Management, LP6.32%2,609,125984.94KSep 29, 2024
Acadian Asset Management. LLC3.05%1,259,151475.33KSep 29, 2024
Vanguard Group Inc2.04%843,844318.55KSep 29, 2024
Sands Capital Ventures, LLC1.91%787,007297.10KSep 29, 2024

Fund ownership

SPRB fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.55%638,558241.06KSep 29, 2024
Vanguard Extended Market Index Fund0.48%197,18774.44KSep 29, 2024
Fidelity Extended Market Index Fund0.37%153,22857.84KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.10%40,00015.10KSep 29, 2024
Fidelity Series Total Market Index Fund0.09%36,51013.78KOct 30, 2024
Fidelity Total Market Index Fund0.08%31,50311.89KOct 30, 2024